The effect of total cumulative dose, number of treatment cycles, interval between injections, and length of treatment on the frequency of occurrence of antibodies to botulinum toxin type A in the treatment of muscle spasticity

International Journal of Rehabilitation Research

Volumn 35, Issue 1, 2012, Pages 36-39

  Bakheit, Abdel Magid O ^a   Liptrot, Anthea ^a   Newton, Rachel ^a   Pickett, Andrew M ^b  

^a Birmingham Community Healthcare NHS Trust ^*  (United Kingdom)

^b Toxin Science Limited   (United Kingdom)

Author keywords

antibodies; botulinum toxin; dose; spasticity

Indexed keywords

BOTULINUM TOXIN; BOTULINUM TOXIN TYPE-A; DOSE; HIGH INCIDENCE; LONG DURATION; NEUTRALIZING ANTIBODIES; SHORT-INTERVAL; SPASTICITY;

BIOASSAY; CHEMICAL DETECTION; PATIENT TREATMENT; TOXIC MATERIALS;

ANTIBODIES;

BOTULINUM TOXIN A; MUSCLE RELAXANT AGENT; NEUTRALIZING ANTIBODY;

ADULT; AGED; ARTICLE; BIOSYNTHESIS; FEMALE; HUMAN; IMMUNOLOGY; MALE; MIDDLE AGED; SPASTICITY; TIME;

ADULT; AGED; ANTIBODIES, NEUTRALIZING; BOTULINUM TOXINS, TYPE A; FEMALE; HUMANS; MALE; MIDDLE AGED; MUSCLE SPASTICITY; NEUROMUSCULAR AGENTS; TIME FACTORS;

EID: 84857192476     PISSN: 03425282     EISSN: None     Source Type: Journal    
DOI: 10.1097/MRR.0b013e32834df64f     Document Type: Article

References (23)

1. Bakheit AMO,Ward AB, Thilmann AF, Poewe W,Wissel J, Muller J, et al. (2000). A randomized, double-blind, placebo-controlled, dose-ranging study to compare the efficacy and safety of three doses of botulinum toxin type A (Dysport) with placebo in upper limb muscle spasticity after stroke. Stroke 31:2402-2406.
2. Bakheit AMO, Pittock S, Moore AP, Wurker M, Przuntek H, Erbguth F, et al. (2001). A randomised, double-blind, placebo-controlled study of the efficacy and safety of botulinum toxin A (Dysport) in upper limb spasticity in patients with stroke. Eur J Neurol 8:559-565. (Pubitemid 35015221)
3. Bakheit AMO, Fedorova NV, Skoromets AA, Timerbaeva SL, Bhakta BB, Coxon L (2004). The beneficial antispasticity effect of botulinum toxin type A is maintained after repeated treatment cycles. J Neurol Neurosurg Psychiatry 75:1558-1561. (Pubitemid 39430607)
4. Bhakta BB, Cozens JA, Bamford JM, Chamberlain MA (2000). Impact of botulinum toxin on disability and carer burden due to arm spasticity after stroke: a andomized double blind placebo controlled trial. J Neurol Neurosurg Psychiatry 69:217-221. (Pubitemid 30466027)
5. Cordivari C, Misra VP, Vincent A, Catania S, Bhatia KP, Lees AJ (2006). Secondary nonresponsiveness to botulinum toxin A in cervical dystonia: the role of electromyogram-guided injections, botulinum toxin A antibody assay and the extensor digitorum brevis test. Mov Disord 21:1737-1741. (Pubitemid 44742209)
6. Dressler D (2004). Clinical presentation and management of antibody-induced failure of botulinum toxin therapy. Mov Disord 19 (Suppl 8):S92-S100. (Pubitemid 38967517)
7. Dressler D, Dirnberger G (2000). Botulinum toxin therapy: risk factors for therapy failure. Mov Disord 15 (Suppl 2):51.
8. Gordon MF, Brashear A, Elovic E, Kassicieh D, Marciniak C, Liu J, et al. (2004). Repeated dosing of botulinum toxin type A for upper limb spasticity following stroke. Neurology 63:1971-1973. (Pubitemid 39532408)
9. Hanna PA, Jankovic J, Vincent A (1999). Comparison of mouse bioassay and immunoprecipitation assay for botulinum toxin antibodies. J Neurol Neurosur Psychiatry 66:612-616. (Pubitemid 29186967)
10. Hatheway CH, Dang C (1994). Immunogenicity of the neurotoxins of Clostridium botulinum. In: Jankovic J, Hallett M, editors. Therapy with botulinum toxin. New York: Marcel Dekker. pp. 93-107.
11. Jankovic J, Schwartz KS (1995). Response and immunoresistance to botulinum toxin injections. Neurology 45:1743-1746.
12. Jankovic J, Vuong KD, Ashton J (2003). Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia. Neurology 60:1186-1188. (Pubitemid 36418786)
13. Kessler KR, Skutta M, Benecke R, for the German Dystonia Study Group (1999). Long-term treatment of cervical dystonia with botulinum toxin type A: efficacy, safety, and antibody frequency. J Neurol 246:265-274. (Pubitemid 29229352)
14. Kranz G, Sycha T, Voller B, Kranz GS, Schnider P, Auff E (2008). Neutralizing antibodies in dystonic patients who still respond to botulinum toxin type A. Neurology 70:133-136.
15. Lange O, Bigalke H, Dengler R, Wegner F, de Groot M, Wohlfarth K (2009). Neutralizing antibodies and secondary therapy failure after treatment with botulinum toxin type A: much ado about nothing? Clin Neuropharmacol 32:213-218.
16. Morte C, Pla F, Cedo M, Mirabet M, Peraire C, Obach R, et al. (2008). A Development of multi-step approach for detection of neutralizing antibodies to botulinum toxin type A. Poster presentation at the symposium "Basic and therapeutic aspects of botulinum and tetanus toxins". Baveno, Lake Maggiore, Italy, 12-15 June.
17. Odergren T, Hjaltason H, Kaakkola S, Solders G, Hanko J, Fehling C, et al. (1998). A double blind, randomised, parallel group study to investigate the dose equivalence of Dysport and Botox in the treatment of cervical dystonia. J Neurol Neurosurg Psychiatry 64:6-12. (Pubitemid 28156530)
18. Rollnik JD,Wohlfarth K, Dengler R, Bigalke H (1997). Neutralizing botulinum toxin type A antibodies: clinical observations in patients with cervical dystonia. Neurol Clin Neurophysiol 2001:1-4.
19. Sankhla C, Jankovic J, Duane D (1998). Variability of the immunologic and clinical response in dystonic patients immunoresistent to botulinum toxin injections. Mov Disord 13:150-154. (Pubitemid 28029867)
20. Siatkowski RM, Tyutyunikow A, Biglan AW, Scalise D, Genovese C, Raikow RB, et al. (1993). Serum antibody production to botulinum A toxin. Ophthalmology 100:1861-1866. (Pubitemid 24004612)
21. Simpson DM, Alexander DN, O'Brien CF, Tagliati M, Aswad AS, Leon JM, et al. (1996). Botulinum toxin type A in the treatment of upper extremity spasticity: a randomized, double-blind, placebo-controlled trial. Neurology 46: 1306-1310. (Pubitemid 26159292)
22. Yablon SA, Brashear A, Gordon MF, Elovic EP, Turkel CC, Daggett S, et al. (2007). Formation of neutralizing antibodies in patients receiving botulinum toxin type A for treatment of poststroke spasticity: a pooled-data analysis of three clinical trials. Clin Therapy 29:683-690. (Pubitemid 47016643)
23. Zuber M, Sebald M, Bathien N, de Recondo J, Rondot P (1993). Botulinum toxin antibodies in dystonic patients treated with type A botulinum toxin: frequency and significance. Neurology 43:1715-1718. (Pubitemid 23307942)